Figure 1.

Serological responses to two doses of the BNT162b2 vaccine according to current treatment in patients with hematological malignancies. Violet bars show data from the study by Maneikis et al. (94) in which the Abott Architect SARS-CoV-2 IgG Quant II immunoassay was used to detect anti-RBD Ab (samples with < 50 AU/mL were considered seronegative) while blue bars show the data from the study from Tzarfati et al. (95) in which SARS-CoV-2 S1/S2 IgG test (samples with < 12 AU/mL were considered seronegative) was used to assess humoral response. Please note that the titers from the two studies cannot be compared given that different serological tests were used. Ab, antibodies; IMiD, Immunomodulatory imide drug; PI, proteasome inhibitor; anti-CD20 Ab, monoclonal antibody targeting CD20 (such as rituximab); BTKi, Bruton tyrosine kinase inhibitor; CT, chemotherapy.